In the case of SMYD1, the majority of alterations were observed as low-level gains in colorectal adenocarcinoma (18.5%), stomach adenocarcinoma (16.1%), lung squamous cell carcinoma (43.1%), lung adenocarcinoma (20%), endometrial carcinoma (17.1%), and uterine carcinosarcoma (46.4%). Here, SMYD1 is linked to gastric adenocarcinoma.